Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

mPharma

25 views

Published on

Presentation to Health Technology Forum, 27SEP17, San Francisco

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

mPharma

  1. 1. mPharmawayne pan, md Nate Braga in M. Butterfly Court Theatre, Chicago Rx
  2. 2. the story of pharma https://en.wikipedia.org/wiki/Drama#/media/File:Comedy_and_tragedy_masks_without_background.svg
  3. 3. science https://en.wikipedia.org/wiki/Drama#/media/File:Comedy_and_tragedy_masks_without_background.svg
  4. 4. science patients https://en.wikipedia.org/wiki/Drama#/media/File:Comedy_and_tragedy_masks_without_background.svg
  5. 5. science patients financing https://en.wikipedia.org/wiki/Drama#/media/File:Comedy_and_tragedy_masks_without_background.svg
  6. 6. & transformationbiomarkers personalized healthcare value-based purchasing traditionmarketing drug discovery development
  7. 7. https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/closing-the-digital-gap-in-pharma
  8. 8. https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/closing-the-digital-gap-in-pharma
  9. 9. conservative compliance global organization long-term investments inertia https://commons.wikimedia.org/wiki/File:Horse_drawn_US_Mail_car.jpg
  10. 10. conservative compliance global organization long-term investments inertia whynow? https://commons.wikimedia.org/wiki/File:Horse_drawn_US_Mail_car.jpg
  11. 11. conservative compliance global organization long-term investments competition business model sustainability innovation inertiaagility https://commons.wikimedia.org/wiki/File:Horse_drawn_US_Mail_car.jpg
  12. 12. http://idealog.co.nz/venture/2015/05/eco-friendly-product-stewardship-makes-dollars-and-sense
  13. 13. conservative compliance global organization long-term investments competition business model sustainability innovation inertiaagility COMPENSATION https://commons.wikimedia.org/wiki/File:Horse_drawn_US_Mail_car.jpg
  14. 14. conservative compliance global organization long-term investments competition business model sustainability innovation inertiaagility COMPENSATION COMPLIANCE https://commons.wikimedia.org/wiki/File:Horse_drawn_US_Mail_car.jpg
  15. 15. conservative compliance global organization long-term investments competition business model sustainability innovation inertiaagility COMPENSATION CULTURE COMPLIANCE https://commons.wikimedia.org/wiki/File:Horse_drawn_US_Mail_car.jpg
  16. 16. understandingthepatient
  17. 17. understandingthepatient behavior genome, proteome biomarkers home monitoring telehealth
  18. 18. expeditingthescience
  19. 19. expeditingthescience machine learning genome, proteome wearables home monitoring diagnostics
  20. 20. enablingthefinancing
  21. 21. enablingthefinancing machine learning big data managing risk organizational agility digital culture
  22. 22. data scientists bioinformaticists behavioral specialists IOT statisticians tech business development learning specialists mobile developers http://colescountydemocrats.com/we-want-you/ managed care
  23. 23. Higher Price Transparency Lower Price Transparency HIGH TECH LOW TECH http://www.expressbpd.com/pharma/it-at-pharma/digitizing-drug-development-how-much-can-it-save/384883/
  24. 24. Higher Price Transparency Lower Price Transparency HIGH TECH LOW TECH Status Quo • Price inflation continues at
 current pace • New innovative products enter
 the market at premium prices • Fewer R&D efficiencies from
 technology http://www.expressbpd.com/pharma/it-at-pharma/digitizing-drug-development-how-much-can-it-save/384883/
  25. 25. Higher Price Transparency Lower Price Transparency HIGH TECH LOW TECH Status Quo • Price inflation continues at
 current pace • New innovative products enter
 the market at premium prices • Fewer R&D efficiencies from
 technology http://www.expressbpd.com/pharma/it-at-pharma/digitizing-drug-development-how-much-can-it-save/384883/
  26. 26. Higher Price Transparency Lower Price Transparency HIGH TECH LOW TECH Status Quo Doomsday • Price inflation continues at
 current pace • New innovative products enter
 the market at premium prices • Fewer R&D efficiencies from
 technology • Public pressure and 
 government action forces put
 downward pressure on drug
 prices as the system moves to
 fee for value • Increased transparency into
 R&D costs • Margins contract http://www.expressbpd.com/pharma/it-at-pharma/digitizing-drug-development-how-much-can-it-save/384883/
  27. 27. Higher Price Transparency Lower Price Transparency HIGH TECH LOW TECH Rainbow’s End Status Quo Doomsday • Innovation continues to be
 rewarded with premium
 pricing • Core basket of drugs continues
 inflating at high double digits • Innovation in biology and 
 technology leads to R&D
 efficiencies and better drugs • Price inflation continues at
 current pace • New innovative products enter
 the market at premium prices • Fewer R&D efficiencies from
 technology • Public pressure and 
 government action forces put
 downward pressure on drug
 prices as the system moves to
 fee for value • Increased transparency into
 R&D costs • Margins contract http://www.expressbpd.com/pharma/it-at-pharma/digitizing-drug-development-how-much-can-it-save/384883/
  28. 28. Higher Price Transparency Lower Price Transparency HIGH TECH LOW TECH Rainbow’s End Status Quo Balancing Act Doomsday • Innovation continues to be
 rewarded with premium
 pricing • Core basket of drugs continues
 inflating at high double digits • Innovation in biology and 
 technology leads to R&D
 efficiencies and better drugs • Price inflation continues at
 current pace • New innovative products enter
 the market at premium prices • Fewer R&D efficiencies from
 technology • Public and government put
 downward pressure on drug
 prices and increases
 transparency for R&D costs • Innovation in biology & tech
 leads to better drugs & R&D
 efficiencies to offset pricing
 pressures • Public pressure and 
 government action forces put
 downward pressure on drug
 prices as the system moves to
 fee for value • Increased transparency into
 R&D costs • Margins contract http://www.expressbpd.com/pharma/it-at-pharma/digitizing-drug-development-how-much-can-it-save/384883/
  29. 29. Higher Price Transparency Lower Price Transparency HIGH TECH LOW TECH Rainbow’s End Status Quo Balancing Act Doomsday • Innovation continues to be
 rewarded with premium
 pricing • Core basket of drugs continues
 inflating at high double digits • Innovation in biology and 
 technology leads to R&D
 efficiencies and better drugs • Price inflation continues at
 current pace • New innovative products enter
 the market at premium prices • Fewer R&D efficiencies from
 technology • Public and government put
 downward pressure on drug
 prices and increases
 transparency for R&D costs • Innovation in biology & tech
 leads to better drugs & R&D
 efficiencies to offset pricing
 pressures • Public pressure and 
 government action forces put
 downward pressure on drug
 prices as the system moves to
 fee for value • Increased transparency into
 R&D costs • Margins contract ?http://www.expressbpd.com/pharma/it-at-pharma/digitizing-drug-development-how-much-can-it-save/384883/
  30. 30. thankyou John Lithgow and B.D. Wong Original Broadway production (1988)
  31. 31. -Why is the pharmaceutical industry now interested in digital health? -What digital technologies is the industry most interested in (increased access to care, medication compliance, etc.) and who are they partnering (looking to partner) with? -What talents are the industry looking to bring in to grow their digital health ventures? -How has Genentech been involved in digital health (that you could share)?

×